This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

National Minority Quality Forum To Launch The National Clinical Trial Network With Microsoft

WASHINGTON, Feb. 15, 2013 /PRNewswire-USNewswire/ -- The National Minority Quality Forum announced today a collaboration between its National Health Index (NHI) and Microsoft Corporation to launch the National Clinical Trial Network (NCTN) designed to address important challenges in clinical trials—accelerating recruitment and diversity.   The relationship allows NCTN to deliver a platform that provides a comprehensive database of clinical trial options to providers.

"It's our view big data will change the way we conduct clinical trials moving forward. What makes the NCTN platform unique is it will provide an interactive, communications portal linking researchers to practicing physicians whose diversity of patients may be candidates for clinical trials," says Gary Puckrein, president and CEO of the National Minority Quality Forum.  "Being able to quickly link the broader community of medical researchers, practicing physicians, tertiary care centers, and allied health professionals together, we can expedite discovery and translational research." 

NCTN will also be a data warehouse (patient registries, bio banks and community-level health statistics), transforming isolated data repositories into an integrated, searchable, national archive, permitting the rapid identification of representative samples of risk populations who might benefit from a proposed therapy.

NCTN will maintain searchable profiles of clinical research institutions, experienced clinical investigators and those interested in being a clinical researcher.  Its investigator registry will provide background information on investigators, their practices and the communities that they serve.

"This collaboration with the National Health Index is truly a 21st century healthcare venture, using big data and Microsoft's proprietary software to give the research community a vast array of information and communications tools," said Michael Robinson, Vice President of U.S. Health and Life Sciences, Microsoft. "We fully expect NCTN to transform clinical research in the United States."

"Biopharmaceutical companies continue to explore new ways to further enhance awareness and participation in clinical trials by a diverse patient population," stated Salvatore Alesci, M.D., Ph.D., Vice President of Scientific Affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA).  "PhRMA applauds partnership efforts such as the National Clinical Trial Network that seek to promote awareness and create connectivity that can translate into increased diversity among clinical trial participants."

NCTN will be introduced fourth quarter 2013.  For more information, please visit www.nctrialnetwork.com.

The National Health Index (NHI) is a wholly–owned subsidiary of the National Minority Quality Forum. NHI provides unparalleled internet access to the most comprehensive reservoir of healthcare information at the zip code level.  Diabetes, heart disease, cancer, HIV/AIDS, Hepatitis C, obesity, and other common and rare chronic diseases represent the NHI repository, powered by a database that represents more than 800 million patient files.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs